RECORD // Company

Praxis Precision Medicines, Inc.

Built 2026-11-22T00:16:35Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (6)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • PRAXIS PRECISION MEDICINES, INC. · Ct business · same registered legal name as 'Praxis Precision Medicines, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Praxis Precision Medicines · Ctgov · exact name match to 'Praxis Precision Medicines, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • PRAXIS PRECISION MEDICINES, INC. · East licences · same registered legal name as 'Praxis Precision Medicines, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • PRAXIS PRECISION MEDICINES, INC. · East licences · same registered legal name as 'Praxis Precision Medicines, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • PRAXIS PRECISION MEDICINES, INC. · East licences · same registered legal name as 'Praxis Precision Medicines, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Praxis Precision Medicines, Inc. · East licences · same registered legal name as 'Praxis Precision Medicines, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001689548-26-000089

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-94,234,0003 months ended 2026-09-3010-Q2026-11-090001689548-26-0000892026-11-22 00:16 UTCReport an error
Cash and cash equivalents$361,851,000at 2026-09-3010-Q2026-11-090001689548-26-0000892026-11-22 00:16 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001689548
Ticker
PRAX
CUSIP
74006W207
Record ID
sx:sec:0001689548

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-18SEC EDGAR company profile2026-11-22 00:16 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-18SEC EDGAR company profile2026-11-22 00:16 UTCReport an error
State of incorporationDE2026-11-18SEC EDGAR company profile2026-11-22 00:16 UTCReport an error
Fiscal year end (MMDD)12312026-11-18SEC EDGAR company profile2026-11-22 00:16 UTCReport an error
Business address99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 021102026-11-18SEC EDGAR company profile2026-11-22 00:16 UTCReport an error
ExchangesNasdaq2026-11-18SEC EDGAR company profile2026-11-22 00:16 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL Revenues2026-11-22 00:16 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-303,268,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:16 UTCReport an error
Total assets (at 2025-12-31)$937,907,0002025-12-3110-K, XBRL Assets2026-11-22 00:16 UTCReport an error
Stockholders' equity (at 2025-12-31)$878,136,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:16 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$357,329,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:16 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-249,068,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:16 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$56,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:16 UTCReport an error
Operating lease liabilities (at 2025-12-31)$110,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:16 UTCReport an error
Form D total offering amount (D filed 2019-06-27)$9,999,9982019-06-27D2026-11-22 00:16 UTCReport an error
Form D total amount sold (D filed 2019-06-27)$9,999,9982019-06-27D2026-11-22 00:16 UTCReport an error
Form D industry groupPharmaceuticals2019-06-27D2026-11-22 00:16 UTCReport an error
Form D revenue rangeDecline to Disclose2019-06-27D2026-11-22 00:16 UTCReport an error
Form D date of first sale2019-06-182019-06-27D2026-11-22 00:16 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-12)On November 12, 2026, Praxis Precision Medicines, Inc. (the “Company”) hosted an Investor Day event (“Investor Day”). The presentation used at Investor Day is available in the “Investors + Media” portion of the Company’s website at investors.praxismedicines.com and a copy is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K under Item 7.01, including Exhibit 99.1, attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated…2026-11-12SEC EDGAR 8-K 0001689548-26-000091 (text as filed, excerpt)2026-11-22 00:16 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-12)On November 12, 2026, at Investor Day, Company management presented on the Company’s commercial strategy and launch plans for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (“DEEs”) and ulixacaltamide in essential tremor (“ET”) and provided an update on its expanded development pipeline. The Company shared the following updates: Ulixacaltamide •The Company provided an updated population-based prevalence estimate for ET of about 9 million people in the U.S., including about 2 million who are seeking treatment today and who represent the Company’s initial commercial focus. •The Company provided sensitivity analyses of the Essential3 primary endpoint, including key…2026-11-12SEC EDGAR 8-K 0001689548-26-000091 (text as filed, excerpt)2026-11-22 00:16 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026. A copy of the press release containing these announcements is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”). The information in this Current Report under Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of…2026-11-09SEC EDGAR 8-K 0001689548-26-000086 (text as filed, excerpt)2026-11-22 00:16 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-06)On August 6, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026. A copy of the press release containing these announcements is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).2026-08-06SEC EDGAR 8-K 0001689548-26-000082 (text as filed, excerpt)2026-11-22 00:16 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-06)On August 6, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available in the “Investors + Media” portion of the Company’s website at investors.praxismedicines.com and a copy is furnished as Exhibit 99.2 to this Current Report. The information in this Current Report under Items 2.02 and 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference…2026-08-06SEC EDGAR 8-K 0001689548-26-000082 (text as filed, excerpt)2026-11-22 00:16 UTCReport an error
Largest institutional holder #1 (13F as filed): Jupiter Topco LLC$1,145,994,0512026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:16 UTCReport an error
Largest institutional holder #2 (13F as filed): FMR LLC$775,677,2792026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:16 UTCReport an error
Largest institutional holder #3 (13F as filed): BlackRock, Inc.$767,534,5322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:16 UTCReport an error
Largest institutional holder #4 (13F as filed): PERCEPTIVE ADVISORS LLC$681,627,7532026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:16 UTCReport an error
Largest institutional holder #5 (13F as filed): BAKER BROS. ADVISORS LP$586,953,1582026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:16 UTCReport an error
Largest institutional holder #6 (13F as filed): Orbis Allan Gray Ltd$512,157,7242026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:16 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$447,006,5862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:16 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$413,565,7522026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:16 UTCReport an error
Largest institutional holder #9 (13F as filed): STATE STREET CORP$343,656,0042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:16 UTCReport an error
Largest institutional holder #10 (13F as filed): ADAGE CAPITAL PARTNERS GP, L.L.C.$339,972,5492026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:16 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.